Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jun Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1418-3576; OpenAlex author ID A5008794639. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
82
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 13

  1. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  2. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  3. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  4. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  5. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
  6. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Co-author DOI 10.1038/s41467-021-27349-7↗
  7. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  8. Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. Co-author DOI 10.7150/jca.48661↗
  9. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  10. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. First author DOI 10.1172/jci.insight.130811↗
  11. DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Co-author PMID 31911850↗
  12. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  13. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haoqiang Ying · 9 shared papers, 2017–2025 · strength 0.89
  2. Huamin Wang · 7 shared papers, 2017–2025 · strength 0.70
  3. Mien‐Chie Hung · 6 shared papers, 2017–2024 · strength 0.63
  4. Anirban Maitra · 5 shared papers, 2018–2024 · strength 0.47
  5. Paul J. Chiao · 4 shared papers, 2017–2024 · strength 0.47
  6. Jason B. Fleming · 5 shared papers, 2018–2024 · strength 0.44
  7. Ronald Anthony Depinho · 4 shared papers, 2017–2025 · strength 0.43
  8. Timothy Paul Heffernan · 4 shared papers, 2019–2025 · strength 0.41
  9. Wantong Yao · 4 shared papers, 2019–2025 · strength 0.41
  10. Ya’an Kang · 4 shared papers, 2018–2024 · strength 0.38
  11. Yongkun Wei · 3 shared papers, 2018–2025 · strength 0.37
  12. Dechun Li · 3 shared papers, 2019–2022 · strength 0.36
  13. Jian Zhou · 3 shared papers, 2019–2022 · strength 0.36
  14. Ching-Fei Li · 2 shared papers, 2024–2025 · strength 0.32
  15. Dihua Yu · 2 shared papers, 2023–2024 · strength 0.27
  16. Yuchen Tang · 2 shared papers, 2021–2022 · strength 0.26
  17. Bin Yi · 2 shared papers, 2021–2022 · strength 0.26
  18. Zixiang Zhang · 2 shared papers, 2021–2022 · strength 0.26
  19. Wenjuan Yin · 2 shared papers, 2021–2024 · strength 0.25
  20. Yan Liang · 3 shared papers, 2019–2021 · strength 0.24
  21. Andrea Viale · 2 shared papers, 2019–2025 · strength 0.23
  22. Dongming Zhu · 2 shared papers, 2019–2022 · strength 0.23
  23. Yijun Wei · 2 shared papers, 2019–2021 · strength 0.22
  24. Jun Zhao · 2 shared papers, 2019–2024 · strength 0.21
  25. Jianhua Ling · 2 shared papers, 2017–2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.